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Improving patient-provider communication
about chronic pain: development and
feasibility testing of a shared decision-
making tool
Nananda Col1* , Stephen Hull2, Vicky Springmann1, Long Ngo3, Ernie Merritt4, Susan Gold5, Michael Sprintz6,
Noel Genova2, Noah Nesin7, Brenda Tierman1, Frank Sanfilippo2, Richard Entel8 and Lori Pbert9
Abstract
Background: Chronic pain has emerged as a disease in itself, affecting a growing number of people. Effective patient-
provider communication is central to good pain management because pain can only be understood from the patient’s
perspective. We aimed to develop a user-centered tool to improve patient-provider communication about chronic
pain and assess its feasibility in real-world settings in preparation for further evaluation and distribution.
Methods: To identify and prioritize patient treatment goals for chronic pain, strategies to improve patient-provider
communication about chronic pain, and facilitate implementation of the tool, we conducted nominal group technique
meetings and card sorting with patients with chronic pain and experienced providers (n = 12). These findings informed
the design of the PainAPP tool. Usability and beta-testing with patients (n = 38) and their providers refined the tool
and assessed its feasibility, acceptability, and preliminary impact.
Results: Formative work revealed that patients felt neither respected nor trusted by their providers and focused on
transforming providers’ negative attitudes towards them, whereas providers focused on gathering patient information.
PainAPP incorporated areas prioritized by patients and providers: assessing patient treatment goals and preferences,
functional abilities and pain, and providing patients tailored education and an overall summary that patients can share
with providers.
Beta-testing involved 38 patients and their providers. Half of PainAPP users shared their summaries with their providers.
Patients rated PainAPP highly in all areas. All users would recommend it to others with chronic pain; nearly all trusted
the information and said it helped them think about my treatment goals (94%), understand my chronic pain (82%), make
the most of my next doctor’s visit (82%), and not want to use opioids (73%). Beta-testing revealed challenges delivering
the tool and summary report to patients and providers in a timely manner and obtaining provider feedback.
Conclusions: PainAPP appears feasible for use, but further adaptation and testing is needed to assess its impact on
patients and providers.
(Continued on next page)
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Background
Chronic pain is one of the most common reasons adults
seek medical care [1]. Opioids became the mainstay of
chronic pain treatment in recent decades. When prop-
erly used, opioid therapy can improve patients’ quality of
life, decrease healthcare costs, and improve work prod-
uctivity. However, misuse and abuse of prescription opi-
oids has reached epidemic proportions (http://www.fda.
gov/Drugs/DrugSafety/InformationbyDrugClass/ucm33
0614.htm). The number of drug overdose deaths in-
creased 4-fold between 1999 and 2018 [2, 3], with
opioid-related deaths accounting for two-thirds of all
drug overdose deaths in 2016 and 2017 [4, 5]. Factors
that drove the overuse of opioids were misinformation
about its benefits and harms [6], inadequate training of
health care providers in pain management, too little
clinic time spent with complex patients, and too few
multidisciplinary treatment programs [7, 8]. Yet pain re-
mains undertreated among those most in need. Today’s
prescription drug crisis reflects a broad failure in man-
aging pain.
Lacking objective measures of pain, healthcare providers
must trust their patients’ words to understand their pain,
its impact on their lives, and their response to treatments.
But pain and its treatments can interfere with patients’
ability to communicate [9]. Because pain can be exagger-
ated for secondary gain (for example, liability tort claims)
or to obtain opioids that can be misused [10, 11], suspi-
cion may be cast on patients with chronic pain [12]. Dif-
ferences between patients’ and providers’ attributions
about causes of pain further erode the trust that is essen-
tial to good communication. Patients who believe their
pain is biologic may feel misunderstood when psycho-
logical treatments are recommended, or frustrated when
no diagnosis is identified [13]. Mandated restrictions to
treatments (such as dosing limits) may be blamed on pro-
viders, reinforcing feelings of distrust [14]. It is not sur-
prising that many patients with chronic pain feel
stigmatized and misunderstood [15] and report being la-
beled as hypochondriacs or drug seekers [16], while pro-
viders feel frustrated and overwhelmed [17, 18].
Helping patients communicate their experiences and
beliefs about their pain, expectations about treatments,
and treatment goals should help providers understand
their patients better, which in turn should improve the
effectiveness of pain management. The quality of pa-
tient–provider communication predicts patient satisfac-
tion better than decreases in reported pain [19–22].
Understanding a patient’s goals, values, and expectations
is essential because these elements serve as filters
through which patients screen their options [23], inter-
pret evidence [24], select treatment [25, 26], and respond
to treatment [27]. Patients’ and providers’ treatment
goals [28] and preferences often diverge [29, 30], reinfor-
cing the need for providers to communicate with pa-
tients about their goals.
Providers can encourage or impede patient involvement
[31]. Providers who engage in partnership-building and
supportive talk create opportunities for patients to discuss
their needs and be involved [32]. Yet providers only occa-
sionally use partnering or supportive communication, in-
form patients when there is a decision to be made, present
all treatment options, or encourage patients to consider
their preferences and goals to guide treatment decisions
[33, 34]. Patients who ask questions and express their con-
cerns and preferences elicit more information and support
from their provider [35–37], but many patients are reluc-
tant to engage in collaborative discussions with providers
for fear of being seen as a “difficult patient” [38]. Simply
asking patients for their preferences is unlikely to yield
meaningful responses because patients often have diffi-
culty applying their values to health decisions [33, 34]. Be-
cause most providers are not taught how to engage
patients in decisions about their health, clinical tools are
needed to help with these tasks.
Shared decision-making (SDM) tools, such as decision
aids, have been shown in clinical trials to help patients
be more informed, experience less decisional conflict, be
more involved in decisions about their health, and be
more likely to choose treatments that are consistent with
their informed preferences and values [39]. However, de-
cision aids for chronic musculoskeletal pain appear far
less effective than those developed for other conditions,
improving only patients’ knowledge about treatment op-
tions [40]. A recent systematic review identified 17 ran-
domized controlled trials of decision aids for chronic
musculoskeletal pain, all targeting specific pain etiologies
(such as hip or knee osteoarthritis). Only four decision
aids addressed conservative management strategies [41–
44]. Most [12] focused on decisions to undergo surgery.
These tools have limited relevance to people with
chronic pain for whom surgical intervention may no lon-
ger be a viable option and whose pain is often multifac-
torial in etiology, requiring multimodal treatment
approaches.
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Utilization of decision support tools in general has
been disappointingly low, perhaps because they are typ-
ically designed with limited input from patients, little at-
tention to factors that drive utilization, and are
uninformed by theory [45]. Patient input, when elicited,
is typically achieved through focus groups, but extracting
patient priorities from these discussions is subjective and
influenced by the investigator’s perspectives [46]. In con-
trast to traditional focus groups, the nominal group
technique (NGT) coupled with card sorting, referred to
as cognitive mapping, minimizes investigator bias, cap-
tures the language of each participant, maintains the au-
tonomy of individual viewpoints, allows equal input by
each participant, and objectively prioritizes and orga-
nizes findings [47–49]. User-centered design has been
proposed as a way to make PDAs more suitable for clin-
ical implementation [50].
To improve utilization, we worked directly with patients
and providers, employing user-centered design methods
that minimize investigator bias to design the tool.
International standards for developing decision aids [51]
recommend that the development process follow a system-
atic process that involves consultation with patients and cli-
nicians. The process should include scoping and design,
developing a prototype, iterative ‘alpha’ testing with patients
and clinicians, and ‘beta’ testing in ‘real life’ conditions be-
fore producing a final version for use and/or further evalu-
ation. However, only about half of the published reports on
decision aids included in the Cochrane review of treatment
and screening decision aids [52] were field tested with
patients and even fewer had been reviewed or tested by cli-
nicians not involved in the development process. Addition-
ally, few described how they reviewed and synthesized
clinical evidence or a distribution strategy.
In order to improve the management of chronic pain,
we aimed to develop a user-centered tool that improves
patient-provider communication about chronic pain.
This manuscript describes findings from cognitive map-
ping, the development of the tool, and patient and pro-
vider responses to the tool.
Methods
Beta-testing study: participants and recruitment strategy
We limited participants to English-speaking adults with
access to the Internet who had a diagnosis of a chronic
musculoskeletal or neurologic pain disorder resulting in
persistent pain lasting over 6 months. We excluded pa-
tients whose pain was primarily gastrointestinal, genito-
urinary, or cardiac in origin because these patients
represent a separate medical entity that requires treat-
ment of the underlying cause. We limited beta-testing
participants to those with an upcoming appointment to
manage their chronic pain within 8 weeks. We included
providers who were doctors of medicine (MD), doctors
of osteopathic medicine (DO), physician assistants (PA),
nurse practitioners (NP), and social workers (MSW) pro-
viding they had 2 or more years of clinical experience
managing 10 or more patients per month with chronic
pain. To ensure that only subjects with a diagnosis of
chronic pain were included, participants could only be
referred by patient advisers or participating providers
who had access to chronic pain patients or patient net-
works. We purposefully selected diverse patients from
different regions of the country. Patient referral net-
works, including the American Chronic Pain Associ-
ation), the Southern Maine Chronic Pain Support
Group, and a network of multiple sclerosis patients with
chronic pain [53] distributed email invitations to their
members. We limited beta-testing referrals to a conveni-
ence sample of providers who manage patients with
chronic pain in Maine and Texas, including pain man-
agement centers, primary care settings, and addiction
and mental health clinics. We sent participating pro-
viders referral cards and emails to distribute to poten-
tially eligible patients. Beta-testing recruitment occurred
between November 15, 2017, and June 4, 2018.
Formative research using cognitive mapping informed
the design of the PainAPP tool. We conducted struc-
tured focus groups using the NGT to identify i) patient
treatment goals and preferences, ii) strategies to improve
the clinical dialogue surrounding chronic pain, and iii)
implementation strategies for distributing the tool, using
previously validated methods [53, 54].
NGT groups of 5–9 patients or providers responded
to one of the following questions: What are the things
you want to accomplish in treating your pain? (only pa-
tients); What would make it easier to communicate with
your doctor [patients] about chronic pain and how to
manage it? (patients and providers); and What are the
top features that we need to design into the tool to make
it both practical and helpful to you in managing your
patients with chronic pain? (only providers).
NGT participants silently wrote down their responses,
which were later shared, consolidated, and ranked by
participants. We later conducted card sorting among a lar-
ger sample to organize treatment goals into meaningful
clusters. We used hierarchical cluster analysis and multi-
dimensional scaling [55–58] to construct a visual repre-
sentation (cognitive map) of the data and identify
conceptual domains based on how frequently items were
sorted into the same category. Figure 1 outlines these
methods. All analyses were performed using SPSS Statis-
tics 23.
The content in PainAPP was guided by findings from
this formative work, relevant theory (Table 1) [59, 60],
and SDM guidelines [61]. PainAPP includes the key ele-
ments identified by patients and providers during cogni-
tive mapping: assessing patient treatment goals and
Col et al. BMC Medical Informatics and Decision Making          (2020) 20:267 Page 3 of 18
preferences, functional abilities, and pain; providing tai-
lored education; and generating a summary that patients
can share with their providers. To elucidate topics iden-
tified by patients and providers, we created short un-
scripted videos of people discussing their actual
experiences with chronic pain. We also created a short
motion graphics video to introduce the tool and explain
its use and navigation [62]. All patient-facing content
was co-written and iteratively revised by people with
chronic pain and reviewed by experienced providers for
scientific accuracy. Usability and beta-testing among pa-
tients further guided the content and design of PainAPP,
resulting in substantial shortening and redesign, includ-
ing splitting the tool into 2 linked parts.
Beta-testing protocol
We emailed a link to the study website to patients who
responded to the study invitation. The link directed
them though the eligibility screener, informed consent
document, and baseline questions. Patients were then
randomized to either PainAPP or the control group
(using Qualtrics’ randomization feature). Baseline ques-
tions were tailored to the assigned study group to avoid
duplication of items that would be subsequently asked in
Fig. 1 Overview of cognitive mapping methods used for PainAPP
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PainAPP. Subjects randomized to PainAPP were emailed a
unique, nontransferable link to the PainAPP tool; control
subjects were directed to the control website (https://www.
theacpa.org/pain-management-tools/communication-tools/).
The control website was chosen based on recommendations
of advisers and published quality ratings [63]. Both
study groups were emailed identical evaluations im-
mediately after viewing the assigned intervention, after
their scheduled provider appointment, and 3–4 weeks
later. Patient participants received an incentive pay-
ment ($25 online gift card) after completing the first
evaluation and a $5 gift card for each subsequent
evaluation; providers received a single $50 gift card.
Beta-testing evaluation and measures
We used a randomized controlled prospective study de-
sign, using an initial 4:1 assignment to PainAPP versus
control to be able to assess uptake and utilization of Pai-
nApp so that any necessary changes could be addressed.
Evaluations obtained after viewing the assigned interven-
tion included: “I would recommend it to others with
chronic pain,” “I trusted the information provided,” “It
helped me think about my treatment goals,” “It presented
unbiased information,” “It addressed topics that are im-
portant in communicating with my doctor,” “It helped me
manage my chronic pain,” “It will help me make the most
of my doctor’s visit,” “It helped me think about the pros
and cons of opioids,” “It changed the way I think about
opioids,” and “It made me not want to use opioid pain
medications.” Survey responses used a 5-point Likert scale
(“strongly agree, somewhat agree, neither agree nor dis-
agree, somewhat disagree, strongly disagree”). Participants
were also asked for their suggestions for improving
PainAPP.
The following measures were assessed after the sub-
jects’ scheduled provider appointment:
Interest in sharing their summary report with their pro-
vider. Subjects were asked: “If you received a personal
summary report, did you try to share your personal sum-
mary report with this provider?” Responses were “yes,”
“no,” “not sure,” and “not applicable—I did not receive a
personal summary.”
Patient-provider communication. Items from the Con-
sumer Assessment of Healthcare Providers and Systems
(CAHPS) Adult, Clinician & Group Survey [64] that
were related to SDM were summed to create a compos-
ite measure.
Satisfaction with communication was assessed by using
the 10-item subscale of the.
The Combined Outcome Measure for Risk Communi-
cation and Treatment Decision Making Effectiveness
(COMRADE) [65]. Scores are summed to produce a
total score (0–20). A higher score corresponds to higher
satisfaction.
Pain Intensity was assessed using The Brief Pain In-
ventory, which rates the severity of pain at its worst,
least, average, and currently, and the degree to which it
interferes with daily activities (walking, work, mood, en-
joyment of life, relations with others, and sleep).
The Control Preference Scale assesses “the degree of
control an individual wants to assume when decisions are
being made about medical treatment,” with roles including
the patient making treatment decisions alone, jointly with
the physician, or the provider making decisions. Collab-
orative roles are generally considered preferable to having
the provider or patient make decisions alone.
Attitudes towards opioids: For people currently using
an opioid, we adapted a survey item related to intention
to stop using or reduce opioids from the Prescribed Opi-
oids Difficulty Scale [66]. For those not currently using
an opioid, we used the questions: “It made me not want
to use an opioid,” “It helped me think about the pros
and cons of opioids,” and “It changed the way I think
about opioids.”
Beta-testing data analysis
All data were directly entered by the patient into a Qual-
trics database. Use of PainAPP pages was monitored via
analysis of website log files. Mean time spent on differ-
ent activities was computed after removing outliers that
likely reflected break periods. We could not directly de-
termine how much time participants spent on the con-
trol website because we did not have access to that
website’s log file. Because of the small sample size, the
limited scope of the beta-testing, and biases detected
during beta-testing, limited statistical analyses were per-
formed. Recruitment was ended before our initial target
of 50 patients was achieved because of serious challenges





Optimize representation All preference items and content
were derived from and organized by
experienced patients
Include all potentially
appropriate options and their
attributes
All relevant attributes of all options
are shown to patients
Suspend selection of an initially
favored option (pre-selection)
Start by focusing only on attributes,
not options. Introduce options
afterwards
Remind decision maker of the
array of values
Includes activities that require
attention to the complete array of
values (broad and narrow): choosing,
ranking, rating
Facilitate weighting of attributes Force selection of top 3, then
ranking, then rating of each
subcomponent.
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discovered that prompted a reassessment of the study
design. The initial target sample of 50 was estimated to
provide an 80% chance of detecting a 20% improvement
on the primary outcome COMRADE with a type-I error
rate of 0.05 [67].
The intervention
PainAPP is an interactive, online decision support
tool that employs a tunnel design [68] to guide users
through a series of structured, interactive modules
(Fig. 2). Multi-tiered values clarification exercises help
users identify and prioritize their treatment goals and
preferences by asking them to select and rank the
most important broad goals from a list of nine do-
mains (for example, “managing pain,” “having a better
quality of life,” and “reducing fear, anger, and depres-
sion”). Next, users are asked to rate the importance
of more detailed goals that are conceptually related to
the goals that were selected, using a 4-point Likert
scale (“not important or does not apply,” “somewhat
important,” “important,” and “very important”). All
pre-programmed treatment goals were generated by
patients with chronic pain during cognitive mapping.
Additional goals can be added by the user. A sum-
mary of the patient’s goals and preferences is gener-
ated along with guidance on using these goals to
manage pain (Fig. 3).
PainAPP consists of 2 linked parts that can be used
independently or sequentially. Part 1 focuses on pa-
tient engagement, clarifying patient goals and prefer-
ences and providing tailored education. Part 2
includes a comprehensive pain assessment (including
risk for opioid misuse, psychosocial comorbidities,
and lifestyle risk factors) coupled with educational
feedback tailored to the patient’s reported risks and
preferences. Information entered in Part 1 is recalled
in Part 2. Both parts generate a succinct structured
summary, shown during use and emailed to the pa-
tient upon completion (Fig. 4). The patient can share
the summary with his or her provider by either copy-
ing it into the patient portal, emailing it, printing it,
or through a mobile device.
The tool emphasizes patient engagement, provider
partnership, and communication. Features include:
accessibility on multiple platforms, scalability, encryp-
tion, HIPAA compliance, and various options for dis-
semination. Content employs principles of effective
communication [34] such as positive framing, side-by-
side comparisons, graphics, encouragements and com-
mendations upon completing sections, plain language,
highlighting of important information, and a user-driven
path. The tool was created using customized Qualtrics©
software (Seattle, WA). The study adheres to CONSORT
guidelines.
Fig. 2 Content diagram of PainAPP
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Results
Part 1. Cognitive mapping
Treatment goals
Sixteen patient subjects consented (50% female, 87%
white, mean age 57 years) and completed the NGT activ-
ities. Two NGTs involving 8 patients each, conducted in
February and April 2016, yielded 37 unique patient-
identified treatment goals. Sixteen patient subjects con-
sented to the card sorting exercise and completed all rat-
ings; 15 completed the card sorting (94%). The 2-
dimensional solution for the multidimensional scaling
analyses indicated robust goodness-of-fit measures
(stress = .1041). The most endorsed goal for patients
(100%) was “To have providers who understand my pain
and limitations” (Table 2). Ten patient clusters were de-
rived from the 37 patient treatment goals. The most im-
portant cluster was Physical activity and stamina,
followed by You and your providers, and Pain manage-
ment. The least important was Medication management.
We interpreted one dimension of the patients’ cogni-
tive map as ranging from factors internally controlled by
the patient to factors externally controlled, the other di-
mension ranging from emotional/social function to
physical/cognitive impact (Fig. 5).
Communication strategies
Three NGTs involved 14 patient participants (67% fe-
male) and 7 provider participants (MD, DO, and PA).
Forty-one unique communication strategies were gener-
ated by patients, 35 by providers. The most important
patient-generated strategies were: “clinician takes me
seriously and respects my input” and “being involved as
an integral part of my treatment team.” The most im-
portant provider-generated strategy was “knowledge of
past work-up,” followed by “timeline of the pain.” Strat-
egies prioritized by both patients and providers were
“improved provider teamwork,” “more time allotted for
consultations,” and “better knowledge about the under-
lying condition.” Both groups prioritized knowledge
about their condition over knowledge about treatment
options (Table 3).
Fig. 3 Sample summary of patient treatment goals and preference
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Clinical integration
We conducted one NGT involving 5 provider partici-
pants. Providers felt the tool would be most helpful if it
helped them assess functional abilities and pain history
(Table 4).
Part 2. Beta-testing findings
Of the 61 patients who opted in and were emailed invi-
tations to participate, 43 (70%) initiated screening, and
of those, 38 (88%) were eligible and consented (Fig. 6).
Completing the intake process took 20.7 min on average;
Patient Engagement and Education (Part 1) took an
average of 28.0 min; Comprehensive Pain Assessment
(Part 2) took an average of 27.3 min. Patients using the
control site reported spending between 15 and 60 min
on the site (average 28 min). Just over half of patients
(56%) were referred by providers, the remainder (44%)
by patient networks. Socio-demographics of participants
are shown in Table 5.
Of the 17 patients who completed both components of
PainAPP, half [7] wanted to share their summary report
with their provider; 3 (37.5%) by printing it and bringing
it to the clinic visit, 3 (37.5%) requested that it be mailed
to them because they do not have a printer, and 2 (25%)
opted to use a patient portal. Among the 16 subjects
assigned to PainAPP who completed the post-provider
visit, half [7] reported trying to share their summary re-
port with their provider, 2 weren’t sure, 2 reported that
it was not applicable because they did not receive it, and
4 did not try to share it. Among the 4 who reported not
sharing their summary, 1 forgot, 1 reported that there
was “no time and [their provider] did not seem that ac-
cessible”; one gave a non-informative response1; and one
offered no explanation. None of the patients in the con-
trol group received a personal summary as this was not
a feature of that website. Curiously, 3 of these 5 control
subjects reported receiving a summary, one of whom re-
ported sharing the summary with his/her provider, one
reported not sharing it because it was received at the
end of the visit, and one was not sure if he/she shared
the summary with the provider.
Half of all subjects (48%) preferred to make the final
treatment selection themselves after seriously consider-
ing their doctor’s opinion, 13% preferred to share re-
sponsibility with their doctor, and 7% preferred their
doctor make the final decision after considering their
opinion; none preferred to leave all decisions to their
provider. Six (35%) of PainAPP users became more en-
gaged with decision making after using the tool, chan-
ging their role preferences toward a more collaborative
or independent role.
Both PainAPP and the control website achieved high
ratings by most subjects on evaluation measures assessed
Fig. 4 Sample provider summary generated by PainAPP
1This response was: “We discuss my fibromyalgia pain and changes
each appointment briefly”
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Table 2 Ratings of prioritized patient treatment goals (“Topics most important to you when you are choosing ways to manage or
treat your chronic pain”)
# Goal Importance Rating
(Mean, SD)
Physical activity and stamina 9.71 0.48
To be able to do more with less pain 9.79 0.41
To have more energy and stamina and less fatigue 9.79 0.56
To pace myself, set reasonable expectations, listen to my body, and know my limitations 9.71 0.45
To be more physically fit (strength and flexibility) within my limitations 9.57 0.49
You and Your Providers 9.62 0.50
To have providers who understand my pain and limitations 10.00 0.00
To have a team of providers who work together to help me 9.71 0.59
To be able to explain better to my providers how I feel 9.14 0.91
Pain Management 9.45 0.62
To reach a point where pain does not control my day 9.79 0.41
To manage pain at a reasonable level 9.50 0.50
To learn more about chronic pain or my condition and how to deal with it better 9.29 0.80
To learn strategies to help me ease my pain 9.21 0.77
To be able to tolerate things like light, odor, noise 8.21 1.15
To reduce pain at night [allowing me to sleep better] 9.07 1.03
Costs 9.29 0.80
To find a treatment [or medical equipment I can afford] 9.29 0.80
To find an alternative treatment I can afford
Living a more independent and satisfying life 9.23 0.80
To travel or commute with more comfort 9.36 0.61
To be able to sit comfortably 9.36 0.81
To be able to live independently in my home 9.21 1.01
To be able to do more household chores 9.00 0.76
To help others 9.57 0.49
To lead a fuller life 9.57 0.62
To be able to work 8.43 1.05
Better memory, thinking, and focus 9.07 0.88
To improve or maintain clear thinking 9.07 0.88
To retain and recall information
To be better able to focus
Managing depression and emotions 8.91 0.91
To be less irritable and able to deal better with stress 9.29 0.80
To be able to look forward to the future instead of being focused on my pain 9.21 1.01
To develop better ways to deal with depression 9.00 1.00
To be able to control anger and aggressive thoughts 8.57 0.90
To reduce my fear of being in pain 8.50 0.82
Friends, family, and intimacy 8.88 1.08
To maintain relationships with family and friends 9.07 0.96
To be able to socialize and reduce isolation 8.86 0.99
To improve or maintain sexual relations 8.71 1.28
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immediately after use (Fig. 7). Because of the small sam-
ple size, high attrition rate, and the small number of
people in the control group, no meaningful comparisons
can be made. Nearly all PainAPP users strongly or some-
what agreed that I would recommend it to others with
chronic pain (100%), It addressed topics that are import-
ant in communicating with my doctor (100%),and I
trusted the information (94%).
Statistical testing of the null hypothesis of no differ-
ence between the study and controls group could not be
Table 2 Ratings of prioritized patient treatment goals (“Topics most important to you when you are choosing ways to manage or
treat your chronic pain”) (Continued)
# Goal Importance Rating
(Mean, SD)
Minimal and natural treatments 8.77 0.76
To avoid side-effects that cause more problems 9.57 0.49
To avoid surgery 9.29 0.80
To be able to handle pain using natural and/or alternative treatments 9.14 0.64
Medication management 8.52 1.12
To minimize or eliminate my pain medications 8.71 1.10
To maintain current level of pain medications 8.29 1.03
To have enough medication to adequately treat my pain 8.57 1.24
To become pain-free regardless of side effects 7.07 1.10
Fig. 5 Cognitive map of patient treatment goals (n = 13)
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done due to small sample size.. Exploratory analyses are
shown in Additional file 1: Appendix 1.
We emailed 12 invitations to evaluate the tool to partici-
pating providers, which yielded one provider’s evaluations
of 2 patients. Both evaluations were non-informative be-
cause the two patients evaluated had not chosen to share
their report with their provider, leading the provider to re-
spond to all questions with “not applicable”. The providers
of patients referred through patient networks could not be
contacted.
No harms or unintended effects were reported.
Discussion
Our formative work confirmed both the challenges and
importance of patient-provider communication in man-
aging chronic pain. The most important single treatment
goal articulated by patients addressed communication—
“having a provider who understand their pain and limi-
tations”. The strategies prioritized by patients to improve
patient-provider communication reveal that patients
with chronic pain felt neither respected nor trusted by
their providers, elements that are essential to effective
communication. Strategies prioritized by providers
reveal their struggles with gathering information about
their patients. While patients focused on transforming
providers’ negative attitudes towards patients with
chronic pain, providers focused on gathering informa-
tion about their patients. Providers prioritized collecting
biologic over psychosocial data, yet many of the treat-
ment goals identified by patients addressed complex
nonbiologic constructs such as preserving independence,
pacing oneself, managing emotions, and obtaining af-
fordable treatments. While few of the communication
strategies prioritized by patients or providers mapped to
key elements of SDM, helping providers with data col-
lection might indirectly promote SDM by freeing up
time to discuss the patient’s preferences and concerns.
Preliminary testing suggests that PainAPP was well-
received by patients, appears user-friendly, and the sum-
mary page appears potentially useful for patients,
whether shared with providers or not. Evaluations ob-
tained just after using the tool were generally favorable
though findings after the provider visit were mixed.
Table 3 Comparison of patient and provider identified
communication strategies to improve chronic pain discussions
Top 10 patient factors Top 10 providers factors
The clinician takes me seriously
and respects my input
Past work-up and outcomes of the
presenting problem/ source of
pain
Be told about all options and side-
effects
Having a clear timeline of the pain
The clinician is knowledgeable
about my particular condition
Hearing how they believe their
pain has impacted their daily lives,
outlook, & relationships
Ask how I want to manage it/
accept that I am in charge of my
health/ I am involved as an integral
part of my treatment team
Listen to their story, allow them to
vent
Take the time needed, not rush Hear the patient's expectations
about their pain
Talk to me not the computer/ make
eye contact/ read the medical file
before, not during, the appointment
A clear history of past treatments
tried and whether they helped or
not
Let me know that he’s
communicated with other docs
taking care of me
Have enough time with the
patient (>30 minutes)
To have an encouraging doctor/
never leave me feeling utterly
helpless, hopeless, or written off
Knowing of any adverse childhood
experiences
Have a trusting relationship with
my provider
Better use of behavioral and
mental health
No judgment/ not look at me as if
I’m faking it/ feel like doctors aren't




Assess patient’s support system*
*signifies that these 2 items were tied for 10th place
Table 4 Top ranked features to improve clinical integration
(providers only)
Rank What are the top features that we need to design into the
tool to make it both practical and helpful to you in
managing your patients with chronic pain?
1 Assess functional abilities and limitations
2 Provide pain history components (location, duration, history of
onset, history of evaluation to date, associated symptoms,
aggravating and ameliorating factors, current treatment, tried but
failed treatment, etc)
3 Presenting a patient prioritized list of the patient’s goals for the
encounter
4 Educate the patient on effectiveness of CBT, ACT and the
emotional components of pain
5 Scripts to guide difficult conversations regarding changing a
longstanding treatment plan
6 Educate the patient that reporting pain will not lead to
prescription for pain med.
7 Screening tools for substance use disorder and/or opioid use
disorder
8 Resource list customized by community (treating substance use
disorder, acupuncturists, osteopaths, chiropractors, massage
therapists, Tai Chi, etc.)
9 Require minimal effort by providers (not have to click too many
boxes or write a whole lot)
10 Easy to read and follow
11 Facilitate the patient providing a signed release to facilitate
obtaining past records in advance of the patient encounter
12 Keep it short
13 Gives multiple choice options which reflect the wide range of
patient/provider possible responses
14 Include tools to help with motivational interviewing regarding
pain and function
15 Easy access to MME calculator
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Overall PainAPP appears feasible for use but more rigor-
ous testing is needed.
Our study highlights several challenges with our user-
centered design process. Systematically identifying and
prioritizing patient and provider goals and communica-
tion strategies using cognitive mapping techniques pro-
vided valuable insights but was very time consuming.
Balancing the priorities of patients with those of pro-
viders in the design of the tool was time-consuming and
difficult to navigate. Early testers tended to add (rather
than remove) sections or features to the tool, resulting
in serial lengthening of the tool. Determining the opti-
mal length of the tool was a formidable challenge. After
many users found the tool too long, it was redesigned,
introduced more skip patterns, emailing content to be
read later, and separating it into two parts connected via
an emailed link. These changes streamlined the tool but
introduced some confusion. Some patients lost the link
to Part 2 or did not understand why there was a Part 2.
Tension between comprehensiveness and brevity per-
meated the development process. Providers requested
detailed information about the patient be included in the
summary page, yet also wanted the summary to be short
and easy to read. Several of the providers who helped
guide the development of PainAPP lacked enthusiasm to
distribute or use the tool with their patients. This could
reflect inadequacies in the summary page content, lack
of integration of the tool into clinical workflow, and/ or
the heavy workload of providers. The NGT may not
have been ideal for identifying implementation strategies
for decision support tools because few participating
providers had direct experience with these tools. In-
cluding providers and practice managers experienced
with decision support may have yielded more robust
findings.
Beta-testing revealed serious flaws with our study de-
sign and the intervention itself that were not previously
identified. High attrition rates likely reflected the coup-
ling of a time-intensive study protocol with a time-
intensive, two-part online intervention. The opt-in pro-
cedures coupled with lengthy consent documents and
baseline surveys required nearly as much time as did the
intervention itself (21 min versus 30 min, respectively).
Most attrition occurred during the intake process, losing
23 (38%) from our invited sample. Attrition was also
high during completion of Part 1 of PainAPP (losing an
additional 10 participants) and Part 2 of PainApp (losing
an additional 3 participants). Intake surveys and assess-
ment evaluations were intentionally administered sepa-
rated from the intervention to minimize patient burden
and help subjects better understand the boundaries of
the intervention, but the use of multiple sequential sur-
veys created confusion, as several patients mistook the
baseline questionnaire for the intervention itself.
Fig. 6 Overview of subject enrollment for beta-testing
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Table 5 Baseline patient participant demographic and clinical characteristics (beta-study) (n = 38)
Characteristic Combined (n = 38) PainAPP (n = 30) Control (n = 8)
Mean age, years (range) 56.5 (22–80) 56.9 (22–75) 55 (41–80)
Gender, n (%)
Male 12 (31.6) 9 (30.0) 3 (37.5)
Female 26 (68.4) 21 (70.0) 5 (62.5)
Race, n (%)
White/Caucasian 32 (84.2) 25 (83.3) 7 (87.5)
Black or African American 2 (5.3) 2 (6.7) 0
Latino or Hispanic 2 (5.3) 1 (3.3) 1 (12.5)
Native American or Alaska Native 2 (5.3) 2 (6.7) 0
Other 0 0 0
Education, n (%)
High school graduate or GED 6 (15.8) 5 (16.7) 1 (12.5)
Some college or 2-year college or technical school 10 (26.3) 7 (23.3) 3 (37.5)
4-year college graduate 10 (26.3) 7 (23.3) 3 (37.5)
More than 4-year college degree 12 (31.6) 11 (36.7) 1 (12.5)
Primary cause of chronic pain (%)
Back pain 14 (36.8) 13 (43.3) 1 (12.5)
Fibromyalgia 6 (15.8) 4 (13.3) 2 (25.0)
Neck pain 4 (10.5) 4 (13,3) 0
Nerve pain 4 (10.5) 3 (10.0) 1 (12.5)
Other musculo-skeletal 8 (21.1) 5 (16.7) 3 (37.5)
Complex Regional Pain Syndrome 1 (2.6) 0 1 (12.5)
Other 1 (2.6) 1 (3.3) 0
Years with chronic pain, Mean (SD; range) 17.53 (12.13; 2–50) 17.45 (13.0; 2–50) 16.13 (8.2; 8–30
Past alcohol or drug problem, n (%) 6 (15.8) 5 (16.7) 1 (12.5)
Current daily tobacco use 8 (21.1) 7 (23.3) 1 (12.5)
Use of opioid medications, n (%)
Yes, currently 17 (44.7) 13 (43.3) 4 (50.0)
Yes, in past but not now 12 (31.6) 10 (33.3) 2 (25.0)
No 9 (23.7) 7 (23.3) 2 (25.0)
Overall health (self-reported)
Excellent 0 0 0
Very good 11 (9.0) 9 (30.0) 2 (25.0)
Good 15 (39.5) 12 (40.0) 3 (37.5)
Fair 12 (31.6) 9 (30.0) 3 (37.5)
Poor 0 0 0
Overall mental or emotional health (self-reported)
Excellent 4 (10.5) 4 (13.3) 0
Very good 9 (23.7) 6 (20.0) 3 (37.5)
Good 13 (34.2) 13 (43.3) 0
Fair 8 (21.1) 5 (16.7) 3 (37.5)
Poor 4 (10.5) 2 (6.7) 2 (25.0)
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Splitting up the intervention into 2 parts compounded
this problem. Our choice of control website further
compromised our analyses. Whether and how partici-
pants used the control site website could not be moni-
tored. Further, many participants were referred to the
study through the sponsor of the control website, which
may have motivated those subjects to give overly positive
evaluations of the control website if randomized to the
control group. The functionalities of the two interven-
tions differed substantially--only PainAPP generated a
sharable summary and assessed goals--making compari-
sons of features only included in one website less mean-
ingful. Comparing PainAPP to standard of care might
have avoided these difficulties. To minimize patient bur-
den, questions that were asked in PainAPP (but not the
control) were not duplicated in the baseline survey for
those assigned to PainAPP. However, this compromised
our pre-post evaluation of PainAPP because these items
were effectively asked after completing parts of the inter-
vention, thus not capturing pre-intervention status. Pai-
nAPP may have altered participants’ perspective and
attitudes when answering questions, given that we
observed a shift in preferences for decision-making after
viewing the intervention. A retrospective pre-post design
may have been more appropriate for this intervention.
Such a design is more sensitive and valid [69] than a
randomized controlled trial if the intervention prompts
a change in the frame of reference that participants use
to assess their attitudes, underestimating the interven-
tion’s effects [70–74].
Embedding PainAPP into the electronic health record
(EHR) should facilitate its integration into clinical work-
flow and minimize many of the difficulties encountered.
Dissemination could be triggered when scheduling ap-
pointments, and the summary page could be automatic-
ally embedded into the patient’s record, facilitating
sharing at point-of-care. With additional resources, Pai-
nAPP could potentially be embedded into EHRs, either
in its entirely or in modules. It could also be customized
to different clinical practices or settings and linked to
quality improvement metrics. PainAPP could also be re-
programmed as a mobile App. However, reprogramming
an interactive tool as complex as PainAPP into either an
EHR or mobile App would be a daunting and error-
Fig. 7 Findings from Beta-testing of PainAPP versus Control (n = 24), prior to provider appointment
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prone undertaking. To integrate PainAPP into clinical
workflow without the benefit of being integrated into an
EHR, PainAPP (or an abbreviated version of PainApp)
should be distributed to patients 1–2 weeks before their
appointments and delivery of their summary report to
their provider should be automated. The PainAPP sum-
mary could replace the cumbersome paper-based med-
ical history form that is often used in waiting rooms.
Our beta-testing provided insights to guide future
evaluation and distribution. Referrals from both pro-
viders and patient-networks appear feasible and cap-
ture different population segments. Referrals from
pain specialists exclude those lacking access to spe-
cialty care; referrals from patient networks exclude
socially isolated patients. Combined approaches for
dissemination, using both provider and patient net-
works, may be the optimum strategy for broad
distribution.
Our study has many limitations. Our sample size for
NGTs and cognitive mapping was small. However, we
were able to achieve model convergence with non-
parametric multidimensional scaling and hierarchical
cluster analysis. Two references support the use of these
methods where the power analysis was carried out via
Monte Carlo simulation with small sample size equiva-
lent to the magnitude of our study’s sample size. One
demonstrates sufficient power for a general multidimen-
sional scaling model with the number of clusters up to 4
[75]. Another examines power issues for hierarchical
cluster models in the correct identification of the “true”
number of partitions and the cluster size and also used
simulation study on a small sample size dataset [76].To
improve the representativeness of the sample, we re-
cruited diverse participants from across the U.S. None-
theless, our small sample size limits the generalizability
of our findings. Our sample appeared representative with
regard to age and gender, though less so with respect to
race [77]. Our pilot study findings relied on self-report,
which may have led to a tendency for more favorable re-
sponses. We did not confirm a diagnosis of chronic pain,
but our referral sources made incorrect diagnoses un-
likely. The tool is designed to be used online or on a
mobile device, thus restricting access for some patients
but expanding reach to others. Attempts to obtain pro-
vider evaluations of the patient encounter were unpro-
ductive. Survey invitations emailed from the study’s
secure Qualtrics server were frequently blocked from
providers’ email servers by institutional firewalls, going
into spam folders. When firewalls could eventually be
bypassed, providers were confused when they received
multiple emails about patients they had seen too long
ago to remember details of the encounter. Some pro-
viders did not understand that they were expected to
complete evaluations even if the patient did not share
the summary page or was in the control group. Further,
we had no contact information for providers of partici-
pants referred through patient networks. Addressing
firewall barriers prior to study initiation and improving
instructions about completing provider surveys may
have helped, as would integration into the EHR.
There appears to be an unmet need of patient-
centered tools to help manage chronic pain. Decision
aids that have been evaluated for chronic musculo-
skeletal pain are less effective than those developed
for other conditions. Furthermore, a public directory
of decision aids does not list any available decision
aids targeting chronic pain [78]. However, a growing
number of mobile pain management Apps are becom-
ing available. A recent review [79] identified 36 mo-
bile pain management Apps, most serving as pain
diary tools. However, most of these apps (69%) did
not involve clinicians in App development, none sys-
tematically engaged patients with chronic pain in de-
velopment, and none were considered to be suitable
for clinical usage due to lack of HIPAA compliance.
That review concluded that there are no pain man-
agement Apps designed for clinical use by physicians.
Given the urgency for deploying new approaches to
tackle the ongoing opioid epidemic, PainAPP has been
embedded into a website (ThePainAPP.com, Additional
file 2: Appendix 2) that does not require provider or pa-
tient referral, removing the need for prescreening or dis-
closure of personal identifiers. To avoid the challenges
introduces by using a linear, sequential design, patients
and providers can choose how they would like to learn—
browsing by topic, using only the Patient Engagement/
Education tool, the Comprehensive Pain Assessment
tool, or both.
Misunderstanding patient treatment preferences is
widespread and can result in unnecessary or even harm-
ful treatments [80]. Improving the lives of patients with
chronic pain requires that patients understand their
choices and the consequences of those choices, and that
providers understand their patients, which requires good
communication between the two. This manuscript illus-
trates the value of conducting beta-testing of SDM tools
in real-world settings before large-scale clinical testing,
consistent with other recommendations [51, 81]. This
study identifies the treatment goals of patients with
chronic pain as well as communication strategies to im-
prove chronic pain discussions from the perspective of
both patients and providers. These findings, coupled
with lessons learned about designing and testing patient-
and clinician-centered tools, may provide useful insights
for other tool developers. PainAPP appears to be feasible
for use at this time, though further adaptation and test-
ing is needed to assess its impact on patients and
providers.
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